Open AccessCapmatinib and gefitinib combination therapy: will EGFR-mutated MET-dysregulated NSCLC “capitulate”?
Author(s) -
Brian Ko,
Balázs Halmos
Publication year - 2018
Publication title -
translational lung cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 41
eISSN - 2226-4477
pISSN - 2218-6751
DOI - 10.21037/tlcr.2018.12.05
Subject(s) - gefitinib , medicine , oncology , lung cancer , targeted therapy , protein tyrosine kinases , cancer research , bioinformatics , epidermal growth factor receptor , cancer , receptor , tyrosine kinase , biology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom